The phase 2 trial of Saroglitazar (a PPAR-α/γ agonist) reported the effect of remission of insulin resistance, atherosclerotic dyslipidemia, and ALT, LCF parameters in patients with NAFLD/NASH (117). Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.